INSM Q3 Sales Surge, Guidance Raise Reinvigorates Thesis

What happened

Insmed's Q3 2026 revenue surged 268% year-over-year, driven by BRINSUPRI's rapid adoption, prompting a 15% stock rally and an upward revision to full-year 2026 sales guidance. This sharply contrasts with the cautious stance in our prior report, which highlighted SG&A outpacing revenue and a valuation penalized by cost growth and pipeline setbacks. The raised guidance suggests that launch-related professional fees are normalizing faster than expected, and BRINSUPRI demand remains robust, directly addressing the primary bear concerns of demand quality and operating leverage. While the earnings miss indicates continued high spending, the market's positive reaction signals renewed confidence in the path to 2027 cash-flow positivity and the core respiratory franchise. We now view the Q3 update as a key inflection that de-risks the base scenario and potentially supports a move toward the bull case if SG&A discipline holds.

Implication

The Q3 results directly address the two thesis-breaker checks from our previous report: BRINSUPRI trajectory and SG&A growth. With 2026 sales guidance raised, the probability of meeting or exceeding the $1.0B BRINSUPRI target increases, strengthening the base case. However, we must see evidence in the 10-Q that professional fees and external launch costs are stepping down sequentially; if not, the raised guidance may still be accompanied by unsustainable cash burn. The next catalyst is the ARIKAYCE sNDA submission in 2H26; a timely filing could unlock the bull value of $145, while any slippage resets expectations lower. We maintain a potential buy but would consider increasing position size if the next quarterly filing shows SG&A growth below revenue growth and continued BRINSUPRI momentum.

Thesis delta

The previous thesis was cautious, awaiting proof that BRINSUPRI demand was durable and that SG&A growth would decelerate. The Q3 sales beat and raised guidance provide that proof on the revenue side, shifting our probability weighting from base toward bull. The main remaining risk is cost control; if SG&A does not moderate, the revenue surge may not translate into improved cash flow, but we now see a clearer path to value appreciation.